Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
2.098 JPY | +0,24% | +1,99% | +4,02% |
Vakgebied
Aantal werknemers: 1 729
Verkoop per activiteit
JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Ethical Pharmaceutical
63,1
%
| 37 006 | 62,2 % | 43 145 | 63,1 % | +16,59% |
Consumer Healthcare
36,7
%
| 22 370 | 37,6 % | 25 086 | 36,7 % | +12,14% |
Other
0,2
%
| 157 | 0,3 % | 152 | 0,2 % | -2,78% |
Verkoop per regio
JPY in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Japan
52,6
%
| 34 864 | 58,6 % | 36 001 | 52,6 % | +3,26% |
Europe
29,5
%
| 20 954 | 35,2 % | 20 153 | 29,5 % | -3,82% |
United Kingdom
10,7
%
| - | - | 7 328 | 10,7 % | - |
Other
7,2
%
| 3 715 | 6,2 % | 4 902 | 7,2 % | +31,95% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sachiaki Ibe
CEO | Chief Executive Officer | 83 | 01-03-72 |
Mitsuhiro Ibe
PSD | President | 52 | 01-04-10 |
Yoshihiro Hiraga
CTO | Chief Tech/Sci/R&D Officer | 66 | 01-06-85 |
Yuki Okazawa
BRD | Director/Board Member | 59 | 01-10-17 |
Comptroller/Controller/Auditor | 65 | 01-07-12 | |
Kenji Kusano
SAM | Sales & Marketing | 60 | 01-04-86 |
Toshiaki Kawagoe
PRN | Corporate Officer/Principal | 63 | 01-04-84 |
Hiroki Kato
PRN | Corporate Officer/Principal | 61 | 01-04-88 |
Hirokazu Endo
AUD | Comptroller/Controller/Auditor | 71 | 01-01-06 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Sachiaki Ibe
CEO | Chief Executive Officer | 83 | 01-03-72 |
Tetsuo Komori
BRD | Director/Board Member | 76 | 01-06-06 |
Yoshihiro Hiraga
CTO | Chief Tech/Sci/R&D Officer | 66 | 01-06-85 |
Mitsuhiro Ibe
PSD | President | 52 | 01-04-10 |
Hiroki Kato
PRN | Corporate Officer/Principal | 61 | 01-04-88 |
Toshiaki Kawagoe
PRN | Corporate Officer/Principal | 63 | 01-04-84 |
Kikuo Nomoto
BRD | Director/Board Member | 87 | 01-06-17 |
Kenji Kusano
SAM | Sales & Marketing | 60 | 01-04-86 |
Seiji Morimoto
BRD | Director/Board Member | 73 | 26-06-20 |
Yuki Okazawa
BRD | Director/Board Member | 59 | 01-10-17 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 53 119 190 | 29 587 059 ( 55,70 %) | 9 039 254 ( 17,02 %) | 55,70 % |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
9 039 100 | 17.02% | 127 333 982 $ | |
1 877 000 | 6.14% | 27 520 330 $ | |
189 000 | 0.04% | 7 239 307 $ | |
267 800 | 0.54% | 6 255 066 $ | |
RIKEN VITAMIN CO., LTD. 0.77% | 258 800 | 0.77% | 4 408 381 $ |
146 800 | 0.03% | 2 380 789 $ | |
289 418 | 1.19% | 1 663 708 $ | |
121 000 | 2.84% | 1 318 372 $ | |
483 000 | 2.20% | 1 011 668 $ | |
MATSUKIYOCOCOKARA & CO. 0.01% | 55 185 | 0.01% | 889 516 $ |
Bedrijfsgegevens
Zeria Pharmaceutical Co., Ltd.
10-11 Nihonbashi Kobuna-cho Chuo-Ku
103-8351, Tokyo
+
http://www.zeria.co.jpSector
Verkoop per activiteit
Verkoop per regio
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+4,02% | 586 mln. | |
+19,27% | 43,18 mld. | |
+24,05% | 23,23 mld. | |
+15,11% | 14,6 mld. | |
+12,33% | 13,54 mld. | |
+38,36% | 11,5 mld. | |
-7,63% | 6,79 mld. | |
-0,05% | 6,79 mld. | |
-8,87% | 5,73 mld. | |
+10,21% | 5,31 mld. |
- Beurs
- Aandelen
- Koers 4559
- Onderneming Zeria Pharmaceutical Co., Ltd.